A topical peptide serum significantly reduced facial expression lines compared to placebo within 15 minutes and sustained improvements over 12 weeks in a double-blind clinical trial.
15 minutesTime to first measurable improvement in expression lines after a single application of the peptide serum
What the researchers found
A line-targeting peptide serum (LTPS) containing neuromodulating peptides significantly improved expression lines compared to placebo at all measured time points — as early as 15 minutes after first application and sustained through 12 weeks of twice-daily use.
Board-certified dermatologist evaluation confirmed the peptide serum outperformed placebo for both expression lines and overall skin health parameters at Weeks 4, 8, and 12. These clinical assessments were supported by objective imaging: VISIA photography and 3D PRIMOS CR wrinkle analysis both substantiated the serum's efficacy. The treatment was well tolerated with no reported safety concerns.
Why it matters
Expression lines are among the most common cosmetic concerns, and many people want alternatives to injectable neuromodulators like botulinum toxin. This study provides double-blind, placebo-controlled evidence that a topical peptide serum can meaningfully reduce wrinkles — offering a non-invasive option backed by clinical-grade imaging data rather than just subjective impressions.
The numbers in context
n=55 · 12-week duration · Fitzpatrick Skin Types I–VI · Improvement seen at 15 minutes, Weeks 4, 8, and 12 · Statistically significant vs placebo at all time points
How the study worked
Fifty-five women aged 35–60 with mild to moderate facial fine lines were randomized to apply either the peptide serum or a placebo serum twice daily for 12 weeks. The study was double-blind and IRB-approved. Short-term effects were assessed 15 minutes after the first application. Long-term results were evaluated at Weeks 4, 8, and 12 using dermatologist grading, self-assessment questionnaires, VISIA clinical photography, and 3D PRIMOS CR imaging for objective wrinkle measurement.
Who was studied
55 healthy women aged 35–60, Fitzpatrick Skin Types I–VI, with mild to moderate facial fine lines and wrinkles
What this study cannot tell us
The study included only 55 female subjects, limiting generalizability to men or larger populations. Specific numerical improvements (percentage reduction in wrinkle depth) were not reported in the abstract. The exact peptide composition of the serum was not disclosed, making it difficult to compare with other peptide products. The 12-week duration, while reasonable, does not address long-term durability of results after discontinuation.
How to read the evidence
This is a randomized, double-blind, placebo-controlled trial — the gold standard for clinical evidence. It earns a Moderate-High grade because of the rigorous design and objective imaging endpoints, though the relatively small sample size of 55 subjects and single-center design prevent a top-tier rating.
When this study was published
Published in 2021, this study remains relevant as consumer demand for topical peptide alternatives to injectable neuromodulators continues to grow.
The bigger picture
Injectable neuromodulators like Botox dominate the anti-wrinkle market, but many consumers want non-invasive alternatives. This trial adds to a growing body of evidence that topical peptide formulations — which mimic the muscle-relaxing action of injectables — can deliver measurable results. As peptide delivery technology improves, topical serums may become a credible first-line option for mild to moderate expression lines.
Questions still open
- What specific neuromodulating peptides were used in the serum, and how do they compare to other commercially available peptide products?
- How long do the anti-wrinkle effects persist after subjects stop using the serum?
- Would the results hold in a larger, more diverse population that includes men and a wider age range?
Common questions
Can a peptide serum really work as well as Botox for wrinkles?
How quickly did the peptide serum start working?
Read the original research
A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum Targeting Expression Lines.
The Journal of clinical and aesthetic dermatology, 14(5), 14-21
Citation
Nguyen, Thu Q; Zahr, Alisar S; Kononov, Tatiana; Ablon, Glynis. (2021). A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum Targeting Expression Lines.. The Journal of clinical and aesthetic dermatology, 14(5), 14-21.